Mengrui Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mengrui Liu has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Ke Cheng
Department of Biomedical Engineering, Columbia University, New York, USA
5 shared publications - Dashuai Zhu
Department of Biomedical Engineering, Columbia University, New York, NY, USA
4 shared publications - Na Yan
Department of Biomedical Engineering, Columbia University, New York, NY, USA
4 shared publications - Kaiyue Zhang
Department of Biomedical Engineering, Columbia University, New York, NY, USA
3 shared publications Savannah Weihang Zhang
Department of Biomedical Engineering, Columbia University, New York, NY, USA
3 shared publicationsShiqi Hu
Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA
3 shared publications
Latest Publications
- Open Access
- 21 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (34)
Screening of anti-metastasis drugs by targeting angiopellosis and cancer cluster extravasation
Metastasis accounts for 90% of cancer-related deaths. Extravasation is a necessary step for cancer metastasis. Currently, there are no drugs that specially target extravasation. Most cancer therapies target either proliferation or angiogenesis. We previously identified “angiopellosis” as the dominant mechanism by which vascular endothelial cells undergo conformational changes and actively “push” circulating cancer cells out of blood vessels. In this study, we developed an image-based high-throughput drug screening assay by coculturing cancer membrane–coated spheres with endothelial monolayers. Through this platform, we identified Bay 61-3606 as a lead angiopellosis inhibitor. Bay 61-3606 substantially reduced cancer cluster extravasation, an activity solely supported by angiopellosis and associated with higher metastatic potential, in both zebrafish and mouse models. Furthermore, Bay 61-3606 decreased distant metastases in murine models of lung carcinoma and triple-negative breast cancer. Mechanistically, Bay 61-3606 targeted the c-Jun amino-terminal kinase signaling pathway, down-regulating COL8A1 expression in endothelial cells and impairing the angiopellosis process.
- 21 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (34)
Open AccessScreening of anti-metastasis drugs by targeting angiopellosis and cancer cluster extravasation
Metastasis accounts for 90% of cancer-related deaths. Extravasation is a necessary step for cancer metastasis. Currently, there are no drugs that specially target extravasation. Most cancer therapies target either proliferation or angiogenesis. We previously identified “angiopellosis” as the dominant mechanism by which vascular endothelial cells undergo conformational changes and actively “push” circulating cancer cells out of blood vessels. In this study, we developed an image-based high-throughput drug screening assay by coculturing cancer membrane–coated spheres with endothelial monolayers. Through this platform, we identified Bay 61-3606 as a lead angiopellosis inhibitor. Bay 61-3606 substantially reduced cancer cluster extravasation, an activity solely supported by angiopellosis and associated with higher metastatic potential, in both zebrafish and mouse models. Furthermore, Bay 61-3606 decreased distant metastases in murine models of lung carcinoma and triple-negative breast cancer. Mechanistically, Bay 61-3606 targeted the c-Jun amino-terminal kinase signaling pathway, down-regulating COL8A1 expression in endothelial cells and impairing the angiopellosis process.
- Open Access
- 29 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (22) , eaed2483
Active protein-capturing hydrogel for broad-spectrum pathogen defense
Proteinaceous agents, including viral particles and allergenic proteins, play central roles in infection, inflammation, and immune dysregulation, yet few materials can broadly neutralize them through direct protein capture. Here, we present an inhalable protein trap (IPT), an active hydrogel that rapidly immobilizes diverse amine-containing biomolecules via NHS-amine chemistry. Structural optimization enables IPT to stably incorporate a high density of reactive NHS esters that remain functional under physiological conditions, allowing efficient protein capture at mucosal surfaces. Upon hydration, powdery IPT rapidly forms an active barrier that covalently traps proteins and proteinaceous particles within minutes. This nonselective capture mechanism allows IPT to bind viral particles, allergens released from pollen or fungi, and soluble immune mediators such as histamine. Across multiple animal models, including allergic rhinitis, pollen-induced allergy, and viral infection, IPT consistently outperformed commercial barrier sprays in blocking pathogenic proteins and mitigating disease progression. These results establish IPT as a versatile platform for broad-spectrum protection at biological interfaces.
- 29 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (22) , eaed2483
Open AccessActive protein-capturing hydrogel for broad-spectrum pathogen defense
Proteinaceous agents, including viral particles and allergenic proteins, play central roles in infection, inflammation, and immune dysregulation, yet few materials can broadly neutralize them through direct protein capture. Here, we present an inhalable protein trap (IPT), an active hydrogel that rapidly immobilizes diverse amine-containing biomolecules via NHS-amine chemistry. Structural optimization enables IPT to stably incorporate a high density of reactive NHS esters that remain functional under physiological conditions, allowing efficient protein capture at mucosal surfaces. Upon hydration, powdery IPT rapidly forms an active barrier that covalently traps proteins and proteinaceous particles within minutes. This nonselective capture mechanism allows IPT to bind viral particles, allergens released from pollen or fungi, and soluble immune mediators such as histamine. Across multiple animal models, including allergic rhinitis, pollen-induced allergy, and viral infection, IPT consistently outperformed commercial barrier sprays in blocking pathogenic proteins and mitigating disease progression. These results establish IPT as a versatile platform for broad-spectrum protection at biological interfaces.
- 21 May 2026
- Published by Oxford University Press (OUP) in European Heart Journal
Intrapericardially injected hydrogel loaded with stromal cell secretome microparticles improves post-infarction myocardial repair in pigs
Background and Aims: Myocardial infarction (MI) stands as a prominent manifestation of cardiovascular events. Most of the regenerative effects of stem cell therapies for MI are paracrine. A clinically translatable strategy that harnesses regenerative secretome while enabling minimally invasive delivery is needed. This study evaluated Regenerative Encapsulated Secretome as Cardiac Acellular Therapy (RESCAT), a formulation composed of cardiac stromal cell-derived secretome encapsulated in microparticles and embedded within a hyaluronic acid hydrogel, delivered via intrapericardial injection in a porcine model of MI. Methods: MI was induced using minimally invasive techniques. RESCAT was administered through clinically feasible intrapericardial delivery. Cardiac structure and function were assessed longitudinally in vivo. After the endpoint, infarct size and cardiomyocyte cell-cycle activity were assessed with histology. Single-nucleus RNA sequencing was performed to characterize cardiomyocyte transcriptional states and identify molecular pathways associated with therapeutic response. Results: RESCAT-treated pigs showed improved cardiac function and reduced infarct size compared with control groups. Enhanced cardiomyocyte cell-cycle activity and alterations in cardiomyocyte functional state were also observed. Single-nucleus transcriptomic analysis identified an FN1-expressing cardiomyocyte subtype linked to the activation of the PI3K-Akt pathway, which plays a role in cell survival and growth. Conclusions: Intrapericardial delivery of RESCAT promotes functional and structural cardiac recovery in a clinically relevant porcine MI model. These findings support a minimally invasive, off-the-shelf acellular therapeutic strategy that enhances endogenous repair mechanisms and provides a foundation for translational development in ischaemic heart disease.
- 21 May 2026
- Published by Oxford University Press (OUP) in European Heart Journal
Intrapericardially injected hydrogel loaded with stromal cell secretome microparticles improves post-infarction myocardial repair in pigs
Background and Aims: Myocardial infarction (MI) stands as a prominent manifestation of cardiovascular events. Most of the regenerative effects of stem cell therapies for MI are paracrine. A clinically translatable strategy that harnesses regenerative secretome while enabling minimally invasive delivery is needed. This study evaluated Regenerative Encapsulated Secretome as Cardiac Acellular Therapy (RESCAT), a formulation composed of cardiac stromal cell-derived secretome encapsulated in microparticles and embedded within a hyaluronic acid hydrogel, delivered via intrapericardial injection in a porcine model of MI. Methods: MI was induced using minimally invasive techniques. RESCAT was administered through clinically feasible intrapericardial delivery. Cardiac structure and function were assessed longitudinally in vivo. After the endpoint, infarct size and cardiomyocyte cell-cycle activity were assessed with histology. Single-nucleus RNA sequencing was performed to characterize cardiomyocyte transcriptional states and identify molecular pathways associated with therapeutic response. Results: RESCAT-treated pigs showed improved cardiac function and reduced infarct size compared with control groups. Enhanced cardiomyocyte cell-cycle activity and alterations in cardiomyocyte functional state were also observed. Single-nucleus transcriptomic analysis identified an FN1-expressing cardiomyocyte subtype linked to the activation of the PI3K-Akt pathway, which plays a role in cell survival and growth. Conclusions: Intrapericardial delivery of RESCAT promotes functional and structural cardiac recovery in a clinically relevant porcine MI model. These findings support a minimally invasive, off-the-shelf acellular therapeutic strategy that enhances endogenous repair mechanisms and provides a foundation for translational development in ischaemic heart disease.
- Top Cited PapersOpen Access
- 5 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 391 (6789) , edau9394
Single intramuscular injection of self-amplifying RNA of Nppa to treat myocardial infarction
Self-amplifying RNA (saRNA) enables sustained protein expression from a single administration. In this study, we developed an intramuscular saRNA-lipid nanoparticle (saNppa-LNP) therapy encoding natriuretic peptide type A ( Nppa ) for cardioprotection. A single injection induced sustained pro–atrial natriuretic peptide (pro-ANP) secretion for 4 weeks; pro-ANP was subsequently cleaved by the cardiac protease corin into active ANP, producing robust cardioprotection in mouse and swine myocardial infarction models. At equivalent doses, saNppa achieved greater efficacy than conventional mRNA. Single-nucleus transcriptomics identified natriuretic peptide receptor 1–positive ( Npr1 + ) endothelial and epicardial cells as primary effectors, with saNppa-LNPs reshaping their paracrine profile to promote cardiomyocyte regeneration and suppress fibrosis. Longitudinal biosafety assessments revealed no systemic toxicity. Together, these results demonstrate that one-shot saNppa-LNP therapy offers durable cardioprotection, supporting the broader potential of saRNA-LNP–based approaches for cardiac therapy.
- 5 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 391 (6789) , edau9394
Top Cited PapersOpen AccessSingle intramuscular injection of self-amplifying RNA of Nppa to treat myocardial infarction
Self-amplifying RNA (saRNA) enables sustained protein expression from a single administration. In this study, we developed an intramuscular saRNA-lipid nanoparticle (saNppa-LNP) therapy encoding natriuretic peptide type A ( Nppa ) for cardioprotection. A single injection induced sustained pro–atrial natriuretic peptide (pro-ANP) secretion for 4 weeks; pro-ANP was subsequently cleaved by the cardiac protease corin into active ANP, producing robust cardioprotection in mouse and swine myocardial infarction models. At equivalent doses, saNppa achieved greater efficacy than conventional mRNA. Single-nucleus transcriptomics identified natriuretic peptide receptor 1–positive ( Npr1 + ) endothelial and epicardial cells as primary effectors, with saNppa-LNPs reshaping their paracrine profile to promote cardiomyocyte regeneration and suppress fibrosis. Longitudinal biosafety assessments revealed no systemic toxicity. Together, these results demonstrate that one-shot saNppa-LNP therapy offers durable cardioprotection, supporting the broader potential of saRNA-LNP–based approaches for cardiac therapy.
- Top Cited Papers
- 11 January 2024
- Published by Springer Nature in Nature Nanotechnology
- Vol. 19 (4) , 565-575
Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity
Lung carcinoma is one of the most common cancers and has one of the lowest survival rates in the world. Cytokines such as interleukin-12 (IL-12) have demonstrated considerable potential as robust tumour suppressors. However, their applications are limited due to off-target toxicity. Here we report on a strategy involving the inhalation of IL-12 messenger RNA, encapsulated within extracellular vesicles. Inhalation and preferential uptake by cancer cells results in targeted delivery and fewer systemic side effects. The IL-12 messenger RNA generates interferon-γ production in both innate and adaptive immune-cell populations. This activation consequently incites an intense activation state in the tumour microenvironment and augments its immunogenicity. The increased immune response results in the expansion of tumour cytotoxic immune effector cells, the formation of immune memory, improved antigen presentation and tumour-specific T cell priming. The strategy is demonstrated against primary neoplastic lesions and provides profound protection against subsequent tumour rechallenge. This shows the potential for locally delivered cytokine-based immunotherapies to address orthotopic and metastatic lung tumours.
- 11 January 2024
- Published by Springer Nature in Nature Nanotechnology
- Vol. 19 (4) , 565-575
Top Cited PapersInhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity
Lung carcinoma is one of the most common cancers and has one of the lowest survival rates in the world. Cytokines such as interleukin-12 (IL-12) have demonstrated considerable potential as robust tumour suppressors. However, their applications are limited due to off-target toxicity. Here we report on a strategy involving the inhalation of IL-12 messenger RNA, encapsulated within extracellular vesicles. Inhalation and preferential uptake by cancer cells results in targeted delivery and fewer systemic side effects. The IL-12 messenger RNA generates interferon-γ production in both innate and adaptive immune-cell populations. This activation consequently incites an intense activation state in the tumour microenvironment and augments its immunogenicity. The increased immune response results in the expansion of tumour cytotoxic immune effector cells, the formation of immune memory, improved antigen presentation and tumour-specific T cell priming. The strategy is demonstrated against primary neoplastic lesions and provides profound protection against subsequent tumour rechallenge. This shows the potential for locally delivered cytokine-based immunotherapies to address orthotopic and metastatic lung tumours.
- 14 March 2021
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-4
Effects of Surfactants on Cu-Co Galvanic Corrosion in Post-CMP Cleaning
In the post CMP cleaning of copper interconnects, the residual particles on copper surface should be removed and the interface corrosion defects between copper and barrier layer cobalt should be minimized. Surfactants are commonly used in post CMP cleaning. In this paper, the effects of different concentrations of two surfactants, linear alkylbenzenesulfonic acid(LABSA) and isooctanol polyoxyethylene ether(JFCE), on the corrosion potential difference of Cu and Co were studied by electrochemical method. The results show that both surfactants can significantly reduce the corrosion potential difference of Cu and Co, and the effect of LABSA is better, also the particles on the surface of copper have obvious removal effect.
- 14 March 2021
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-4
Effects of Surfactants on Cu-Co Galvanic Corrosion in Post-CMP Cleaning
In the post CMP cleaning of copper interconnects, the residual particles on copper surface should be removed and the interface corrosion defects between copper and barrier layer cobalt should be minimized. Surfactants are commonly used in post CMP cleaning. In this paper, the effects of different concentrations of two surfactants, linear alkylbenzenesulfonic acid(LABSA) and isooctanol polyoxyethylene ether(JFCE), on the corrosion potential difference of Cu and Co were studied by electrochemical method. The results show that both surfactants can significantly reduce the corrosion potential difference of Cu and Co, and the effect of LABSA is better, also the particles on the surface of copper have obvious removal effect.